Search - tctmd.com

Displaying 521 - 540 of 3327

Sort: Relevancy | Date

News Conference News AHA 2023

AI Improves Detection of Cardiomyopathy in Pregnancy

L.A. McKeown

November 15, 2023

News Conference News AHA 2023

New CVD Risk Tool Can Spur Even Earlier Talk About Prevention

Yael L. Maxwell

November 14, 2023

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

Todd Neale

November 13, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

News Conference News AHA 2023

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

L.A. McKeown

November 13, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

News Conference News AHA 2023

Intensive BP Reduction Lowers Dementia Risk in China Rural Hypertension Study

Todd Neale

November 12, 2023

News Conference News AHA 2023

Slash Dietary Sodium, Slash Blood Pressure: CARDIA-SSBP

Michael O'Riordan

November 12, 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP-Lowering KARDIA-1

News Conference News AHA 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Caitlin E. Cox

November 11, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Conference News AHA 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

Todd Neale

November 07, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Conference News VIVA 2023

‘Dire’ Lack of Vascular Care in Underserved Areas Needs Creativity, Compassion

L.A. McKeown

November 03, 2023

News Daily News

Very High LDL Cholesterol Declines in US Adults, but Progress Is Slow

Michael O'Riordan

November 02, 2023

News Opinion CV Team Dispatch

November 2023 News Roundup

L.A. McKeown

November 01, 2023

News Daily News

FDA Approves First Extravascular ICD

Yael L. Maxwell

October 23, 2023

News Daily News

For Predicting CV Risk, Life’s Essential 8 Doesn’t Add Much to Simple 7

Caitlin E. Cox

October 23, 2023

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

Advertisement

AI Improves Detection of Cardiomyopathy in Pregnancy

New CVD Risk Tool Can Spur Even Earlier Talk About Prevention

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Intensive BP Reduction Lowers Dementia Risk in China Rural Hypertension Study

Slash Dietary Sodium, Slash Blood Pressure: CARDIA-SSBP

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

What’s Going to Be Hot at AHA 2023

‘Dire’ Lack of Vascular Care in Underserved Areas Needs Creativity, Compassion

Very High LDL Cholesterol Declines in US Adults, but Progress Is Slow

November 2023 News Roundup

FDA Approves First Extravascular ICD

For Predicting CV Risk, Life’s Essential 8 Doesn’t Add Much to Simple 7

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content